Abbott Libre Duo 10 Day: The First Glucose and Ketone Sensor, Explained

Abbott’s Libre Duo 10 Day is the first wearable sensor authorized by the FDA to track both glucose and ketones continuously, built to warn people with diabetes about rising ketones before diabetic ketoacidosis sets in.

Presented By Our Partners

The short verdict

Libre Duo is the most meaningful change to continuous glucose monitoring since sensors became small enough to forget you are wearing them. For people who take insulin, the most dangerous short term complication is not a single high glucose reading. It is diabetic ketoacidosis, which builds when the body lacks insulin and starts breaking down fat for fuel. Until now, catching rising ketones meant a separate finger prick or urine strip, usually only when someone already felt sick. Libre Duo moves ketone checks into the same always on sensor that already tracks glucose.

The open questions are practical ones: what it will cost, how insurers will cover it, and how clinicians will want patients to act on mildly elevated ketone readings. Abbott has not answered the first two yet, and diabetes specialists are still writing guidance for the third.

Libre Duo 10 Day at a glance

• Maker: Abbott Diabetes Care
• Measures: interstitial glucose and ketones, continuously
• Wear time: up to 10 days per sensor
• Indicated for: people with diabetes aged 2 and older who take insulin or certain other diabetes medications
• FDA status: De Novo authorization announced August 25, 2026 (DEN250049)
• Europe: CE mark received in May 2026
• Insulin pump integration: designed for automated insulin delivery; Beta Bionics iLet and Sequel twiist support expected by the end of 2026
• US launch: planned for later in 2026
• Price: not yet announced

What is Libre Duo?

Libre Duo 10 Day is Abbott’s first dual analyte sensor. Like the FreeStyle Libre sensors already on the market, it is a small wearable sensor that reads the fluid just under the skin. The difference is a second sensing chemistry for ketones, which the body produces when it burns fat because there is not enough insulin to use glucose.

The system is designed to alert users when ketone levels start rising and again if they reach a concerning threshold. The goal is to buy time: early warning signs of rising ketones, such as fatigue, nausea or thirst, are easy to mistake for an ordinary illness, and by the time someone feels clearly unwell, DKA may already be developing.

Why continuous ketone monitoring matters

Current diabetes guidelines tell people to check ketones during illness or when glucose stays high. In practice, many people do not keep blood or urine ketone tests at home, or rarely use them. That gap matters most for people on insulin pumps, where a blocked infusion set can cut off insulin delivery for hours without obvious symptoms, and for children, where DKA can progress quickly.

Featured Partner

Invest in the Infrastructure Behind Modern Medicine

As healthcare expands beyond hospital walls, the buildings and campuses supporting that shift are generating compelling returns for investors who move early. The Healthcare Real Estate Fund offers qualified investors direct access to a curated portfolio of medical office, outpatient, and specialty care facilities.

Learn More →

Abbott’s diabetes leadership told MedTech Dive the company hopes the device will reduce hospital admissions by making people aware of rising ketones earlier. The FDA’s review found that Libre Duo tracked clinically meaningful changes in ketone levels across the 10 day wear period and detected elevated ketones before the onset of DKA in the studies it reviewed.

FDA status and the clinical evidence

The FDA authorized Libre Duo through the De Novo pathway, which is used for novel devices that have no existing equivalent on the market. Abbott announced the authorization on August 25, 2026, and the FDA announced it the same day. The agency based its decision on six clinical studies that enrolled more than 600 people aged 2 and older and evaluated accuracy for both glucose and ketone monitoring.

Libre Duo is the first system to meet both the FDA’s integrated continuous glucose monitoring (iCGM) standard and a new standard for integrated continuous glucose and ketone monitoring. That second designation is what allows it to feed data into automated insulin delivery systems, which could eventually let a pump respond to ketone trends as well as glucose.

Price, insurance, and availability

Abbott says it will launch Libre Duo 10 Day in the US later in 2026. It has not published a price, and diabetes experts interviewed by MedTech Dive raised cost and insurance coverage as the biggest unknowns. Abbott has said it plans to work with insurers and payers and has emphasized its record of keeping Libre sensors accessible.

Abbott has not yet published US ordering details. Its existing insulin user CGMs, such as FreeStyle Libre 3 Plus, are prescription devices, so expect to need a prescriber to get started. If you use a FreeStyle Libre today, your diabetes care team is the right first call once Abbott confirms launch timing.

Insulin pump and app compatibility

At authorization, Abbott said it expects Libre Duo to work with Beta Bionics’ iLet and Sequel Med Tech’s twiist automated insulin delivery systems by the end of 2026, and that it is working on integrations with other pump makers, including Insulet and Tandem Diabetes Care. Readings will appear in Abbott’s existing Libre app, so current Libre users should not need to learn a new interface.

Who Libre Duo is for

• People with type 1 diabetes, especially those on insulin pumps, where an interrupted infusion can raise ketones quickly.
• Parents of children with diabetes, since the indication starts at age 2.
• People with type 2 diabetes who take insulin or certain other diabetes medications covered by the indication.
• Anyone with a history of DKA or frequent sick days who currently relies on finger prick ketone strips.

It is not a ketone tracker for keto dieting or fasting. The authorization covers diabetes management, and the alert thresholds are built around DKA risk.

How Libre Duo compares with today’s CGMs

Every other CGM on the US market measures glucose only. The closest comparisons are Abbott’s own FreeStyle Libre 3 Plus and the Dexcom G7, both of which integrate with insulin pumps but leave ketone checks to separate strips. Over the counter glucose sensors such as Dexcom Stelo target people who do not use insulin and are not designed for DKA prevention. For a needle free direction in glucose sensing, see our Biolinq Shine review.

Limitations and open questions

• Cost and coverage: unknown until Abbott launches. A second analyte could raise the price over glucose only sensors.
• Clinical guidance: diabetes specialists are still developing guidelines on how to act on continuous ketone readings, especially mild elevations that would never have been caught by occasional strip testing.
• Pump support timing: integration with the most widely used pumps depends on partners and is not yet confirmed beyond iLet and twiist.
• Confirmatory testing: any alert of high ketones should be handled using the sick day plan from your care team, which may include a confirmatory blood ketone test and urgent care.

Related insulin delivery coverage

• twiist for type 2 diabetes: FDA clearance and trial results
• Beta Bionics Mint: FDA cleared patch pump, launch date and CGMs

Frequently asked questions

When will Libre Duo be available in the US?

Abbott plans to launch Libre Duo 10 Day in the US later in 2026. It received FDA De Novo authorization on August 25, 2026, after earning a CE mark in Europe in May 2026.

How much will Libre Duo cost?

Abbott has not announced pricing or insurance coverage as of October 20, 2026. The company says it plans to work with insurers and payers.

Who can use Libre Duo?

The FDA authorization covers people with diabetes aged 2 and older who take insulin or certain other diabetes medications.

Does Libre Duo work with insulin pumps?

Yes, it is designed for automated insulin delivery. Abbott expects compatibility with Beta Bionics iLet and Sequel twiist by the end of 2026 and is working with other pump makers.

Can Libre Duo be used for keto diets?

No. It is authorized for diabetes management and DKA prevention, not for tracking nutritional ketosis.

Sources

• MedTech Dive: Abbott receives FDA nod for dual analyte sensor (August 25, 2026)
• MedTech Dive: 5 questions on Abbott’s glucose ketone sensors (August 19, 2026)
• FDA De Novo database: DEN250049

This article is for general information and is not medical advice. Talk with your diabetes care team before changing how you monitor glucose or ketones.

Free Daily Briefing

The Latest Longevity Science.
Delivered Every Morning.

Join researchers, physicians, and health professionals getting daily breakthroughs in AI-driven medicine, epigenetics, and longevity research.

Support the research that powers this editorial

Subscribe Free

No spam. Unsubscribe anytime. We respect your inbox.

Keep Reading on Healthcare Discovery

• The Daily Rounds: Longevity & Health Care Brief | June 1, 2026
• The FDA’s New AI Experiment Asks a Better Question: Did the Patient Get Better?
• The Protein Threshold for Aging Muscle: Why Adults Over 40 Need More Than Government Guidelines Suggest